Program
HU-045
A development code.
Its studies are led by Huons Global.
Furthest: phase 3, since Jan 4, 20243 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huons Global | 32 open or running | phase 3since Jan 4, 2024 | Mar 16, 2022 | May 2027phase 3 · NCT07870694 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 16, 2022First study: phase 2 study in Glabellar LinesFirst studyNCT05298449 · 50 enrolled · Korea, Republic of
- Jan 4, 2024Phase 3 study in Glabellar LinesNCT06205797 · 312 planned · Korea, Republic of
- Oct 6, 2026Phase 3 study in Glabellar LinesNCT07870694 · 390 planned · South Korea
Ahead
- May 2027Primary completion: phase 3 study in Glabellar LinesNCT07870694
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07870694Glabellar Lines · South Korea | 3 | Recruiting | May 2027 | 390 |
| NCT06205797Glabellar Lines · Korea, Republic of | 3 | Recruiting | Nov 30, 2024 | 312 |
| NCT05298449Glabellar Lines · Korea, Republic of | 2 | Completed | Nov 7, 2022 | 50 |
How it is read
Names in the registry
- “HU-045”, 3 entries
Codes read as this program: HU045.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.